Lyme Science Blog

The Senate’s unanimous passing of Bill C-442, An Act to Create a Federal Framework on Lyme disease, provides hope and promise for both current and future Lyme disease patients. The following article, entitled “No Coordination of Care in Canadian Health Care,” published recently in The Medicine Hat News, describes the struggles that are all-too typical for so many Canadians

While many of the points addressed in the Bill have been agreed upon by all stakeholders at the meeting, certain wording within the bill has created concern for infectious disease specialists, who argue that it suggests support for ‘pseudo-science’ treatment guidelines, while dismissing current evidence-based guidelines put forth by the Infectious Disease Society of America

While the journal authors acknowledge that field studies indicate confirmed endemic areas or potential, future risk areas for ticks has grown from 1 region in 1997 to 13 regions in 2006, the authors minimize the growing concern of tick-borne illness in Canada. They point to the minor number of reported cases. In 2013, 500 cases were reported in Canada.  However, the number of reported Lyme disease

Guest Blog By Jennifer Bybel Lown,  Nurse Practitioner Dr. Daniel Cameron & Associates While Lyme disease isn’t necessarily rare, it is a less understood disease, surrounded by conflicting information. And, one in which, all too frequently, family members seem to be more knowledgeable than medical professionals. We recently treated a patient who had been sick

If the FDA gets its way, physicians would only have access to diagnostic tests for tick borne diseases that are FDA approved.  This would eliminate “specialty labs,” and severely restrict a clinicians ability to diagnose Lyme disease, as well as other tick-borne co-infections. This is a dangerous move in a period when we’re seeing an

A read of the International Lyme and Associated Diseases Society (ILADS) 2014 evidence based guidelines says otherwise.  The ILADS guidelines focus on the risk of poor outcomes such as chronic neurologic Lyme disease, Lyme encephalopathy, and post-Lyme disease syndrome. The ILADS guidelines highlight the poor evidence using the Institute of Medicine’s recommended evidence grading system.  The

Fibromyalgia and Lyme disease symptoms can include muscle pain, fatigue, sleep disturbances, gastrointestinal complaints, difficulty concentrating, headaches and temperature, light and sound sensitivities. Women are also more likely to be diagnosed with the condition. According to the National Institutes of Health, between 80% and 90% of people diagnosed with fibromyalgia are women. The treatments, unfortunately, are not

The task force by Executive Order must submit an action plan by February 15, 2015, outlining specific steps on how to implement a national strategy to combat antibiotic resistance and accelerate research and development on new antibiotics by 2020. The task force will be led by the secretaries of Health and Human Services, the Department